New hope for rare cancer: drug combo shows promise in angiosarcoma trial
NCT ID NCT01303497
First seen Mar 27, 2026 · Last updated May 08, 2026 · Updated 5 times
Summary
This study tested whether adding a targeted drug called bevacizumab to standard chemotherapy (paclitaxel) helps control advanced angiosarcoma, a rare cancer of blood vessels. About 70 adults with inoperable or metastatic disease took part. The main goal was to see how many patients had their cancer stop growing or shrink after 6 months of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre René Gauducheau
Saint-Herblain, 44805, France
-
Centre Val d'Aurelle
Montpellier, 34298, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31052, France
-
Institut Curie
Paris, 75005, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, 42270, France
Conditions
Explore the condition pages connected to this study.